Levetiracetam attenuates diabetes-associated cognitive impairment and microglia polarization by suppressing neuroinflammation
Frontiers in Pharmacology · 04.05.2023 · 14
DOI: 10.3389/fphar.2023.1145819 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.05.2023. Verfasst von Yun-Yun Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Cognitive impairment is a common complication and comorbidity of diabetes. However, the underlying mechanisms of diabetes-associated cognitive dysfunction are currently unclear. M1 microglia secretes pro-inflammatory factors and can be marked by CD16, iNOS, Iba1 and TNF-ɑ. The decline of M2 microglia in the diabetic rats indicates that high glucose promotes the differentiation of microglia into the M1 type to trigger neuroinflammatory responses. Moreover, there is a lack of strong evidence for treatments of diabetes-associated cognitive impairment in addition to controlling blood glucose.
Methods
Diabetic rats were established by intraperitoneal injection of one dose of streptozotocin (60 mg/kg). Polarization transitions of microglia were induced by high glucose treatment in BV2 cells. Levetiracetam was orally administered to rats 72 h after streptozotocin injection for 12 weeks.
Results
In STZ-induced diabetic rats, the results demonstrated that levetiracetam improved rat cognitive function ( Morris water maze test ) and hippocampus morphology ( Hematoxylin-eosin staining ), and the effect was more evident in the high-dose levetiracetam group. Microglia activation in the hippocampus was inhibited by levetiracetam treatment for 12 weeks. Serum levels of TNF-α, IL-1β, and IL-6 were reduced in the LEV-L and LEV-H groups, and IL-1β level was obviously reduced in the LEV-H group. In vitro, we found that levetiracetam 50 µM attenuated high-glucose induced microglial polarization by increasing IL-10 level and decreasing IL-1β and TNF-α levels. Moreover, levetiracetam 50 µM increased and decreased the proportion of CD206+/Iba1+ and iNOS+/Iba1+cells, respectively. Western blot analysis illustrated that LEV 50 µM downregulated the expression of MyD88 and TRAF6, and phosphorylation of TAK1, JNK, p38, and NF-κB p65. The effect of levetiracetam on the anti-polarization and expression of p-JNK and p-NF-κB p65 were partly reversed by anisomycin (p38 and JNK activators).
Discussion
Together, our data suggest that levetiracetam attenuates streptozotocin-induced cognitive impairment by suppressing microglia activation. The in vitro findings also indicate that the levetiracetam inhibited the polarization of microglia via the JNK/MAPK/NF-κB signaling pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Practice, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
- Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, China.
Zitieren
APA
Zhang, Y. Y., Wang, L., Guo, H., Han, T. T., Chang, Y. H., & Cui, X. C. (2023). Levetiracetam attenuates diabetes-associated cognitive impairment and microglia polarization by suppressing neuroinflammation. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1145819
Vancouver
Zhang YY, Wang L, Guo H, Han TT, Chang YH, Cui XC. Levetiracetam attenuates diabetes-associated cognitive impairment and microglia polarization by suppressing neuroinflammation. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1145819
BibTeX
@article{Zhang2023,
author = {Zhang, Yun-Yun and Wang, Lu and Guo, Hua and Han, Ting-Ting and Chang, Yan-Hua and Cui, Xiao-Chuan},
title = {Levetiracetam attenuates diabetes-associated cognitive impairment and microglia polarization by suppressing neuroinflammation},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1145819}
}
EUVIMED